Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Quadrivalent Human Papillomavirus Vaccine in Boys and Girls 9–13 Years of Age in Malaysia: A Phase IIIb, Randomized, Open-label Study

BACKGROUND: Incorporating dengue vaccination within existing vaccination programs could help improve dengue vaccine coverage. We assessed the immunogenicity and safety of a quadrivalent human papillomavirus (HPV) vaccine administered concomitantly or sequentially with a tetravalent dengue vaccine (C...

Descripción completa

Detalles Bibliográficos
Autores principales: Hassan, Jamiyah, Toh, Teck-Hock, Sivapunniam, Selva Kumar, Hasim, Ruziaton, Ghazali, Nor Faizah, Sulaiman, Sofiah, Koh, Mia Tuang, Meyer, Stephanie, Toh, Myew-Ling, Zocchetti, Celine, Vigne, Claire, Mascareñas, Cesar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Vaccine Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8274580/
https://www.ncbi.nlm.nih.gov/pubmed/34250977
http://dx.doi.org/10.1097/INF.0000000000003164

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8274580/
https://www.ncbi.nlm.nih.gov/pubmed/34250977
http://dx.doi.org/10.1097/INF.0000000000003164

Ejemplares similares